SYNLOGIC, INC. Finance Lease, Right-of-Use Asset, Amortization
SYNLOGIC, INC. (SYBX) reported Finance Lease, Right-of-Use Asset, Amortization of $188.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2020-03-12
- SYNLOGIC, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $47.00K.
- SYNLOGIC, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $47.00K.
- SYNLOGIC, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $47.00K.
- SYNLOGIC, INC. finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $47.00K.
- SYNLOGIC, INC. finance lease, right-of-use asset, amortization for fiscal 2019 was $188.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2019-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $94.00K derived: sum of 2 quarters · filed 2020-03-12 | $141.00K derived: sum of 3 quarters · filed 2020-03-12 | $188.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $47.00K 10-Q · filed 2019-11-12 | $94.00K derived: sum of 2 quarters · filed 2019-11-12 | $141.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $47.00K 10-Q · filed 2019-08-08 | $94.00K 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $47.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |